<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099277</url>
  </required_header>
  <id_info>
    <org_study_id>17364</org_study_id>
    <secondary_id>J1Q-MC-JZIA</secondary_id>
    <nct_id>NCT04099277</nct_id>
  </id_info>
  <brief_title>A Study of LY3435151 in Participants With Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug LY3435151 is safe in participants with
      advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to strategic business decision by Eli Lilly and Company.
  </why_stopped>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with LY3435151 Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 2 (21 Day Cycles)</time_frame>
    <description>Number of Participants with LY3435151 DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3435151</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 5 Day 1 (21 Day Cycles)</time_frame>
    <description>PK: Cmax of LY3435151</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3435151 in Combination with Pembrolizumab</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 5 Day 1 (21 Day Cycles)</time_frame>
    <description>PK: Cmax of LY3435151 in Combination with Pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Disease Progression or Death (Estimated up to 12 Months)</time_frame>
    <description>ORR: Percentage of Participants with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 12 Months)</time_frame>
    <description>DCR: Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated up to 12 Months)</time_frame>
    <description>TTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Cervical Carcinoma</condition>
  <condition>High Grade Serous Ovarian Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Undifferentiated Pleomorphic Sarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>LY3435151 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3435151 administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3435151 + Pembrolizumab Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3435151 and Pembrolizumab administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3435151 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3435151 administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3435151 + Pembrolizumab Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3435151 and Pembrolizumab administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3435151</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3435151 + Pembrolizumab Dose Escalation</arm_group_label>
    <arm_group_label>LY3435151 + Pembrolizumab Dose Expansion</arm_group_label>
    <arm_group_label>LY3435151 Dose Escalation</arm_group_label>
    <arm_group_label>LY3435151 Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3435151 + Pembrolizumab Dose Escalation</arm_group_label>
    <arm_group_label>LY3435151 + Pembrolizumab Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have certain types of cancer, which your study doctor will discuss
             with you

          -  Participant must have stopped other forms of treatment for cancer, which your study
             doctor will discuss with you

          -  Participant must be able and willing to provide a sample of your tumor before
             beginning treatment and once while on treatment. For certain tumor types, the outcome
             of the biopsy may exclude you from the study treatment (for Phase 1b)

          -  Participant must agree to use birth control

          -  Participant must have progressed through or are intolerant to therapies with known
             clinical benefit, which your study doctor will discuss with you

        Exclusion Criteria:

          -  Participant must not have a history of tuberculosis, uncontrolled HIV or uncontrolled
             hepatitis B or C virus infection

          -  Participant must not have an autoimmune disease, which your study doctor will discuss
             with you

          -  Participant must not use corticosteroids, which your study doctor will discuss with
             you

          -  Participant must not have heart disease, Crohn's disease or brain cancer

          -  Participant must not be pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/JZIA#?postal=</url>
    <description>A Study of LY3435151 in Participants With Solid Tumors</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>CD226 agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

